Sugi Predict

Sugi Predict / Compounds / SCHEMBL1855313

SCHEMBL1855313

SCHEMBL1855313

CS(=O)(=O)N([CH]c1ccccc1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NR3C2 P08235 2/20 0.37
▸ RELA Q04206 1/20 0.35
▸ CA12 O43570 2/20 0.35
▸ CA9 Q16790 2/20 0.35
▸ CA2 P00918 2/20 0.35
▸ TRPM8 Q7Z2W7 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ CYP2A6 P11509 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ KEAP1 Q14145 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ AKR1C3 P42330 1/20 0.33
▸ HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6950234 0.79 NR3C2 (0.39) NR3C2CA12CA9CA2ALDH1A1
SCHEMBL20679715 0.78 NR3C2 (0.39) NR3C2CA12CA9CA2ALDH1A1
SCHEMBL28365320 0.73 NR3C2 (0.35) NR3C2CA12CA9CA2ALDH1A1
SCHEMBL1850750 0.72 KMT2A (0.43) RELAALDH1A1MEN1KMT2APKM
SCHEMBL1850854 0.72 NR3C2 (0.41) NR3C2RELACA12CA9CA2
SCHEMBL28852905 0.71 PPARG (0.44) RELAALDH1A1MEN1HTTKMT2A
SCHEMBL28852830 0.71 NFE2L2 (0.47) NR3C2RELAMEN1KMT2APKM
SCHEMBL1704542 0.69 PKM (0.50) NR3C2CA12CA9CA2ALDH1A1
SCHEMBL2513199 0.69 NR3C2 (0.44) NR3C2CA12CA9CA2ALDH1A1
SCHEMBL28852827 0.69 TRPA1 (0.53) RELATRPM8ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 — — US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 — — EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 — — US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 — — WO disclosed
WO-2009071888-A1 PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 — — EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA NR3C2 2581/4885RELA 890/4885CA12 4876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.